A previous study has revealed that the SGLT2 inhibitor empagliflozin ameliorates myocardial fibrosis by inhibiting the formation and deposition of collagen via the TGF-β1/Smad pathway in the mouse model of type 2 diabetes mellitus (T2DM) (Li et al., 2019). This evidence concerns the gene SLC5A2 and diabetes mellitus.